HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lövqvist, A. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Lövqvist, A. Articles by Larson, S. M.

PET Imaging of ⁸⁶Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between ⁸⁶Y and ¹¹¹In Radiolabels

Nuclear Medicine Service, Departments of Radiology and Medical Physics, Memorial Sloan-Kettering Cancer Center, New York; Ludwig Institute for Cancer Research, New York, New York; Ludwig Institute for Cancer Research, Austin and Repatriation Medical Center, Heidelberg, Victoria, Australia; and Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland

Absorbed doses in ⁹⁰Y radioimmunotherapy are usually estimated by extrapolating from ¹¹¹In imaging data. PET using ⁸⁶Y (ß⁺ 33%; half-life, 14.7 h) as a surrogate radiolabel could be a more accurate alternative. The aim of this study was to evaluate an ⁸⁶Y-labeled monoclonal antibody (mAb) as a PET imaging agent and to compare the biodistribution of ⁸⁶Y- and ¹¹¹In-labeled mAb. Methods: The humanized anti-Lewis Y mAb hu3S193 was labeled with ¹¹¹In or ⁸⁶Y through CHX-A''-diethylenetriaminepentaacetic acid chelation. In vitro cell binding and cellular retention of radiolabeled hu3S193 were evaluated using HCT-15 colon carcinoma cells, a cell line expressing Lewis Y. Nude mice bearing HCT-15 xenografts were injected with ⁸⁶Y-hu3S193 or ¹¹¹In-hu3S193. The biodistribution was studied by measurements of dissected tissues as well as by PET and planar imaging. Results: The overall radiochemical yield in hu3S193 labeling and purification was 42% ± 2% (n = 2) and 76% ± 3% (n = 6) for ⁸⁶Y and ¹¹¹In, respectively. Both radioimmunoconjugates specifically bound to HCT-15 cells. When cellular retention of hu3S193 was studied using ¹¹¹In-hu3S193, 80% of initially cell-bound ¹¹¹In activity was released into the medium as high-molecular-weight compounds within 8 h. When coadministered, in vivo tumor uptake of ⁸⁶Y-hu3S193 and ¹¹¹In-hu3S193 reached maximum values of 30 ± 6 and 29 ± 6 percentage injected dose per gram and tumor sites were easily identifiable by PET and planar imaging, respectively. Conclusion: At 2 d after injection of ¹¹¹In-hu3S193 and ⁸⁶Y-hu3S193 radioimmunoconjugates, the uptake of ¹¹¹In and ⁸⁶Y activity was generally similar in most tissues. After 4 d, however, the concentration of ⁸⁶Y activity was significantly higher in several tissues, including tumor and bone tissue. Accordingly, the quantitative information offered by PET, combined with the presumably identical biodistribution of ⁸⁶Y and ⁹⁰Y radiolabels, should enable more accurate absorbed dose estimates in ⁹⁰Y radioimmunotherapy.

Key Words: ⁸⁶Y • PET imaging • radioimmunotherapy • Lewis Y • 3S193 antibody

This article has been cited by other articles:

				G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications Oncologist, December 1, 2007; 12(12): 1379 - 1389. [Abstract] [Full Text] [PDF]

				W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]

				V. Kenanova, T. Olafsen, L. E. Williams, N. H. Ruel, J. Longmate, P. J. Yazaki, J. E. Shively, D. Colcher, A. A. Raubitschek, and A. M. Wu Radioiodinated versus Radiometal-Labeled Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy Cancer Res., January 15, 2007; 67(2): 718 - 726. [Abstract] [Full Text] [PDF]

				M. P. Kelly, F. T. Lee, F. E. Smyth, M. W. Brechbiel, and A. M. Scott Enhanced Efficacy of 90Y-Radiolabeled Anti-Lewis Y Humanized Monoclonal Antibody hu3S193 and Paclitaxel Combined-Modality Radioimmunotherapy in a Breast Cancer Model J. Nucl. Med., April 1, 2006; 47(4): 716 - 725. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]

				L. R. Perk, G. W.M. Visser, M. J.W.D. Vosjan, M. Stigter-van Walsum, B. M. Tijink, C. R. Leemans, and G. A.M.S. van Dongen 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab J. Nucl. Med., November 1, 2005; 46(11): 1898 - 1906. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF]

				S. Shen, A. Forero, A. F. LoBuglio, H. Breitz, M.B. Khazaeli, D. R. Fisher, W. Wang, and R. F. Meredith Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies J. Nucl. Med., April 1, 2005; 46(4): 642 - 651. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and C. Divgi Current Status of Therapy of Solid Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S. [Abstract] [Full Text] [PDF]

				I. Verel, G. W.M. Visser, and G. A. van Dongen The Promise of Immuno-PET in Radioimmunotherapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 164S - 171S. [Abstract] [Full Text] [PDF]

				D. E. Gonzalez Trotter, R. M. Manjeshwar, M. Doss, C. Shaller, M. K. Robinson, R. Tandon, G. P. Adams, and L. P. Adler Quantitation of Small-Animal 124I Activity Distributions Using a Clinical PET/CT Scanner J. Nucl. Med., July 1, 2004; 45(7): 1237 - 1244. [Abstract] [Full Text] [PDF]

				I. Verel, G. W.M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma, and G. A.M.S van Dongen Quantitative 89Zr Immuno-PET for In Vivo Scouting of 90Y-Labeled Monoclonal Antibodies in Xenograft-Bearing Nude Mice J. Nucl. Med., October 1, 2003; 44(10): 1663 - 1670. [Abstract] [Full Text] [PDF]

				S. Palm, R. M. Enmon Jr., C. Matei, K. S. Kolbert, S. Xu, P. B. Zanzonico, R. L. Finn, J. A. Koutcher, S. M. Larson, and G. Sgouros Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI J. Nucl. Med., July 1, 2003; 44(7): 1148 - 1155. [Abstract] [Full Text] [PDF]

				T. F. Massoud and S. S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes & Dev., March 1, 2003; 17(5): 545 - 580. [Full Text] [PDF]

				G. L. Griffiths, S. V. Govindan, R. M. Sharkey, D. R. Fisher, and D. M. Goldenberg 90Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin's Lymphoma J. Nucl. Med., January 1, 2003; 44(1): 77 - 84. [Abstract] [Full Text] [PDF]

				S. Shen, R. F. Meredith, J. Duan, D. J. Macey, M.B. Khazaeli, F. Robert, and A. F. LoBuglio Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy J. Nucl. Med., September 1, 2002; 43(9): 1245 - 1253. [Abstract] [Full Text] [PDF]